- About Us
- Career Center
- Nano-Social Network
- Nano Consulting
- My Account
The Nano Science and Technology Institute (NSTI) Invites Researchers to Submit Abstracts for the Merck Corporate Symposium on Targeted Delivery of siRNA, Taking Place During Nanotech 2008 in Boston, MA, USA
The Nano Science and Technology Institute (NSTI) is pleased to announce that abstracts are being accepted for the Merck Corporate Symposium: Targeted Delivery of siRNA, which will be held exclusively during NSTI Nanotech 2008 June 1-5 in Boston, MA. The Symposium will provide a significant platform for Merck to engage leading researchers in the nano tech community and focus discussion around the application of emerging nano technologies and their ability to affect targeted delivery of therapeutic siRNA molecules.
The Merck Corporate Symposium will focus on enabling technologies that can be applied to the efficient delivery of siRNA in vivo which results in reduced levels of specific mRNAs/proteins. In addition, technologies useful for the accelerated development of siRNA containing therapeutics are relevant. Specific areas of interest include:
• Biodegradable delivery components with low levels of toxicity
• Delivery systems for multiple tissues
• Delivery approaches amenable to alternate routes of administration
• Enhanced siRNA delivery using molecular targeting strategies
• Improved siRNA intracellular trafficking, endosomal escape and RISC incorporation
• Advanced siRNA structures which improve in vivo potency, stability, duration of action, specificity and toxicity profiles
• Whole animal methods for efficiently evaluating biodistribution and gene silencing
• Analytical methods for the physical and chemical characterization of complex assemblies
"Merck is pleased to partner with the NSTI in bringing the Symposium to Boston," said Dr. Reid Leonard, Merck's Executive Director of Licensing and External Research. "Nanotech 2008 reflects our commitment to innovation and provides an ideal forum for the presentation of siRNA enabling technologies - an area where Merck has assumed a leadership role."
Entering its 11th year, Nanotech 2008 is the world's largest and most comprehensive technical and business event in nanotechnology. "Merck's Corporate Symposium is one of the most anticipated programs at next year's conference," noted Dr. Matthew Laudon, Executive Director of the Nano Science and Technology Institute. "We are very pleased that Merck, one of the world's most prominent pharmaceutical companies, has partnered with our conference to help address their company's advanced research needs."
To participate in the Merck Corporate Symposium, please submit your abstract through the NSTI Nanotech On-Line Abstract Submission form. The abstract deadline is December 6th, 2007.
The Nano Science and Technology Institute (NSTI) is chartered with the promotion and integration of nano and other advanced technologies through education, technology and business development. NSTI accomplishes this mission through its offerings of continuing education programs, scientific and business publishing and community outreach. NSTI produces the annual Nanotech conference and trade show, the most comprehensive international nanotechnology convention in the world. NSTI also produces the semi-annual Nanotech Venture, Nanotech Industrial Impact Workshop, Nano Impact Summit and the Nanotech Course Series in the US and Europe. NSTI was founded in 1997 as a result of the merger between various scientific societies, and is headquartered in Cambridge, Massachusetts with additional offices in California and Switzerland.
For more information, please click here
696 San Ramon Valley Blvd., Ste. 423
Danville, CA 94526
Ph: (925) 901-4959
Fax: (925) 886-8461
Copyright © NSTIIf you have a comment, please Contact us.
Issuers of news releases, not 7th Wave, Inc. or Nanotechnology Now, are solely responsible for the accuracy of the content.
|Related News Press|
Fast, efficient sperm tails inspire nanobiotechnology December 5th, 2016
UTSA study describes new minimally invasive device to treat cancer and other illnesses: Medicine diffusion capsule could locally treat multiple ailments and diseases over several weeks December 3rd, 2016
Nanobiotix Provides Update on Global Development of Lead Product NBTXR3: Seven clinical trials across the world: More than 2/3 of STS patients recruited in the “act.in.sarc” Phase II/III trial: Phase I/II prostate cancer trial now recruiting in the U.S. November 28th, 2016
Leti IEDM 2016 Paper Clarifies Correlation between Endurance, Window Margin and Retention in RRAM for First Time: Paper Presented at IEDM 2016 Offers Ways to Reconcile High-cycling Requirements and Instability at High Temperatures in Resistive RAM December 6th, 2016
IEDM: Leti CEO Marie Semeria to Give Opening-day Keynote on Impact of ‘Hyperconnectivity’ and IoT: Speech to Portray Key Role Nonprofit Research and Technology Organizations Play in Making Technology More Efficient and Ensuring Safety and Security November 29th, 2016
Cutting-edge nanotechnologies are breaking into industries November 18th, 2016